Key result
Dapagliflozin treatment significantly improved PCOS symptoms, recovered ovarian morphology, reduced apoptosis, and lowered pro-inflammatory cytokines in a rat model.
Why the study?
PCOS is associated with chronic low-grade ovarian inflammation, but the role of dapagliflozin in regulating PCOS remains unclear.
Does dapagliflozin improve ovarian dysfunction and reduce inflammation in a rat model of PCOS?
Does dapagliflozin improve ovarian dysfunction and reduce inflammation in a rat model of PCOS?
Dapagliflozin ameliorates ovarian dysfunction and reduces inflammation in a rat model of PCOS, suggesting potential therapeutic benefits for this condition.
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder associated with chronic low-grade inflammation of the ovary. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a class of antidiabetic drugs that can reduce the weight and hyperglycemia of type 2 diabetes patients. Dapagliflozin is a highly selective, orally active and reversible inhibitor of the human SGLT2. However, the role of dapagliflozin in regulating PCOS remains unclear. METHODS: In this study, 24 six-week-old female Sprague Dawley (SD) rats were randomly divided into control, letrozole, and letrozole + dapagliflozin groups. PCOS model rats were produced by gavage administration of letrozole for 21 days. The intervention was conducted after the gavage administration of dapagliflozin for 14 days to evaluate the estrous cycle and ovarian imaging changes of the rats in each group. We observed changes in the weight, ovarian weight, and ovarian morphology of the rats in each group. Pathological changes in the ovaries were examined by H&E staining, changes in ovarian tissue cell apoptosis were identified using TdT-mediated dUTP Nick-End Labeling (TUNEL) staining, and changes in inflammation-related factors were detected using immunohistochemistry and Western blotting analysis. Network pharmacology was used to predict the inflammatory targets and pathways affected by dapagliflozin in treating PCOS, and the potential interactions between dapagliflozin and inflammation-related target proteins were evaluated through molecular docking. RESULTS: Our results demonstrated that dapagliflozin treatment significantly improved PCOS symptoms, recovered ovarian morphology and physiological functions, and reduced the apoptosis of ovarian cells after drug intervention. Dapagliflozin treatment also reduced the levels of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, indicating its anti-inflammatory properties. Furthermore, network pharmacology identified 26 intersecting target genes relevant to inflammation in PCOS, with subsequent molecular docking simulations revealing strong binding affinities of dapagliflozin to key targets, including AKT1 and TP53. CONCLUSIONS: These findings suggest that dapagliflozin exerts beneficial effects on PCOS by ameliorating ovarian dysfunction and reducing inflammation. Dapagliflozin represents a promising therapeutic candidate for managing PCOS, warranting further clinical investigation to explore its full potential in treating this multifaceted disorder.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dapagliflozin in PCOS; human trials required before any clinical consideration.
No takes yet. Share an insight, caveat, or question.
Y et al. (2025) studied Polycystic ovary syndrome (PCOS) (n=24). Dapagliflozin vs. Control and letrozole groups was evaluated on PCOS symptoms, ovarian morphology, physiological functions, apoptosis, and pro-inflammatory cytokines. Dapagliflozin treatment significantly improved PCOS symptoms, recovered ovarian morphology, reduced apoptosis, and lowered pro-inflammatory cytokines in a rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: